Grace Therapeutics, Inc.

GRCE Healthcare Biotechnology

In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

1.89 0.06 −3.08%
Market cap
$41.0M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
n/a
Altman Z
3.31
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
11.47 8.10 14.96 13.89
Net Debt/EBITDA
0.86 5.65 7.63 6.67
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.19) (0.10) (0.13) (0.20)
Book value per Share
2.79 3.87 3.83 3.94
Free Cash Flow
(3.22) (1.69) (2.23) (3.14)
Other line items

Show all line items

Columns are period end dates